Mesoblast (MESO) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Mesoblast (MESO) has outperformed Sarepta Therapeutics (SRPT) over the past year, losing 22.9% versus a loss of 24.3%. Over five years, MESO leads with a +22.7% price change compared with -79.2% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.85 billion vs $1.81 billion), about 1.0 times the size.
On valuation, Sarepta Therapeutics trades at a lower forward P/E (7.3x vs 30.6x for Mesoblast).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MESO | SRPT |
|---|---|---|
| Share price | $13.94 | $17.50 |
| Market cap | $1.81B | $1.85B |
| 1-day change | +2.42% | +1.10% |
| YTD return | -22.73% | -18.68% |
| 1-year return | -22.94% | -24.31% |
| 5-year return | +22.71% | -79.21% |
| Forward P/E | 30.64 | 7.26 |
| EPS (TTM) | $-0.45 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.50 | $24.68 |
| 52-week low | $13.05 | $14.68 |
| Distance from 52-week high | -35.16% | -29.09% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +165.42% | +24.17% |
| Average volume | 232.53K | 2.98M |
| Shares outstanding | 129.85M | 105.63M |
| Employees | 108 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
MESO vs SRPT FAQ
Which is bigger, Mesoblast or Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.85B compared with $1.81B for Mesoblast (MESO).
Which stock has performed better over the past year, MESO or SRPT?
MESO returned -22.94% over the past 12 months, compared with -24.31% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Mesoblast and Sarepta Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Mesoblast and Biotechnology: Pharmaceutical Preparations for Sarepta Therapeutics.